Literature DB >> 24652385

Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.

Michelangelo Fiorentino1, Francesca Giunchi, Annalisa Altimari, Piergiorgio Di Tullio, Elisa Gruppioni, Giuseppe Martorana, Carmine Pinto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24652385      PMCID： PMC3983821          DOI： 10.1634/theoncologist.2013-0346

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  3 in total

1.  High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.

Authors:  Alcides Chaux; Julie S Cohen; Luciana Schultz; Roula Albadine; Sana Jadallah; Kathleen M Murphy; Rajni Sharma; Mark P Schoenberg; George J Netto
Journal:  Hum Pathol       Date:  2012-03-09       Impact factor: 3.466

2.  Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

Authors:  Kelly N Blehm; Philippe E Spiess; Jolanta E Bondaruk; Melanie E Dujka; Gabriel J Villares; Yi-Jue Zhao; Oliver Bogler; Kenneth D Aldape; H Barton Grossman; Liana Adam; David J McConkey; Bogdan A Czerniak; Colin P Dinney; Menashe Bar-Eli
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.

Authors:  Shi-Xu Jiang; Kazuya Yamashita; Michiko Yamamoto; Chun-Ji Piao; Atsuko Umezawa; Makoto Saegusa; Tsutomu Yoshida; Masato Katagiri; Noriyuki Masuda; Kazushige Hayakawa; Isao Okayasu
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396
  3 in total
  1 in total

Review 1.  Novel molecular targets for urothelial carcinoma.

Authors:  Bishoy M Faltas; Beerinder S Karir; Scott T Tagawa; Jonathan E Rosenberg
Journal:  Expert Opin Ther Targets       Date:  2015-01-30       Impact factor: 6.902
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.